A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents
Latest Information Update: 13 Sep 2023
At a glance
- Drugs Narsoplimab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Omeros Corporation
- 08 May 2023 The trial has been completed in Lithuania, according to European Clinical Trials Database record.
- 24 Dec 2022 The trial has been completed in Poland, according to European Clinical Trials Database record.
- 08 Sep 2016 Status changed from not yet recruiting to recruiting, as reported by an Omeros Corporation media release.